Navigation Links
Contract Research Organization WCCT Global Announces Milestone for Clinical Study Completion
Date:12/26/2013

Costa Mesa, CA (PRWEB) December 26, 2013

WCCT Global, a full service CRO headquartered in Southern California is pleased to announce a new company wide milestone for the quickest completion of a Clinical Study. WCCT Global was able to take a study from final protocol to last subject completion in just two weeks. This accomplishment is testament to the efficiency of the entire WCCT Global study implementation process. The company has made a commitment to be as efficient as possible for all sponsors. The timeline consisted of WCCT Global being awarded the study on December 3rd and received final protocol on December 5th. Screening consisted of 54 subjects were screened from December 12th through December 17th. The study volunteers checked in on December 18th and completed the study on December 19th. The clinical research coordinating staff at WCCT Global is structured in a way where they can implement all aspects of the study to perform in the most efficient way possible.

WCCT Global’s recruitment department played an intricate role in the study’s success by selecting possible volunteers for the study from their fully engaged “opt-in” database. The volunteers were able to quickly be screened and randomized. This process is testament to the patient recruitment process that WCCT Global has been recognized for industry wide. WCCT Global’s Recruitment Manager Sean Lopez stated, “I am proud to announce this great feat with completing this study in the 2 week timeline. It is our goal for every clinical study to offer sponsors the quickest recruitment programs available.” WCCT Global continues to pioneer what is possible from a full service contract research organization.

More About WCCT Global

WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including first-in-human (FIH), as well as specific therapeutic expertise in allergy, asthma, HCV, ophthalmology, oncology, renal, and vaccines.

If you would like to learn more about WCCT Global, click here.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11447383.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Arminco, Inc. Awarded Contract to Design Alexandria Dental Office of Parker-Gray Pediatric Dental Care
2. Key Joy West Expands their Business from Custom Cable Assembly to Custom Contract Manufacturing
3. DXE Medical Named a Top Federal Government Contractor in Nashville
4. Contractors who worked in conflict zones suffer high rates of PTSD, depression
5. Global Pharmaceutical Contract Manufacturing Market
6. Contract Research Organization WCCT Global Announces Clinical Trial Patient Recruitment Services for International Clinical Studies
7. LogicNets® Announces Contract Award from PALGA Dutch National Pathology Network
8. Texas-Based Agency, Weiser Insurance, Warns Houston Residents of the Increased Danger of Contracting Dengue Fever This Fall
9. Managed Care Advisors Wins BPA Contract Award From Department of Homeland Security for Workers' Compensation Medical Case Management Services
10. FDAnews Management Report: Managing Contract Manufacturers and Testing Labs
11. Restoration Local Seeking Water Damage Repair Contractors To Join Their Network Of Service Provider
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... 2017 , ... CareSet Labs released the Root NPI Graph today at the ... greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. , ... called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable ... that visits to the dentist fit into their patients’ busy lifestyles. Dental365 also ...
(Date:6/23/2017)... CA (PRWEB) , ... June 23, 2017 , ... By ... earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ... the top 1% of all charities reviewed by Charity Navigator and earns ANRF a ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend ... entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger to ... years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/13/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... Food and Drug Administration (FDA) has notified the Company that ... Zhejiang, China manufacturing facility has been ... clearance of the Warning Letter related to our ... of the progress we have made in our ongoing quality ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
Breaking Medicine Technology: